Additionally, those taking higher GLP-1 doses (2.4 mg semaglutide weekly or equivalent) often experience more pronounced GI sensitivity during the first 48 weeks and may benefit from temporary dairy reduction
Semaglutide cuts risk of heart attack, stroke or death by 57% vs tirzepatide owenhaskins Aug 31, 2025 2 min read Outcomes form the STEER real-world study have revealed that semaglutide 2.4 mg had 57% greater risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause, in people with overweight or obesity and CVD, who did not have any gaps in their treatment lasting more than 30 days, compared with tirzepatide
In addition, GLP-1 treatment in elderly dogs increased latency for heart disease development and reduced mortality (Chen, Angeli, Shen & Shannon, 2014)
Semaglutide is ideal for individuals who: Have struggled with weight loss despite diet and exercise
Physical activity is limited
We used HepG2 cells treated with Oleic Acid (OA) as a model of hepatic steatosis in this study to see if direct activation of the GLP-1R with Ex-4 affects any of the four processes listed above and thus improves steatosis